September 19, 2013
JCR Pharmaceuticals announced on September 17 an agreement with GlaxoSmithKline (GSK) under which GSK will return to JCR all rights to a recombinant erythropoietin (EPO) biosimilar used to treat renal anemia. Up to now, GSK has held all development and...read more